Genentech, a member of the Roche Group, has begun construction of its first East Coast manufacturing site in Holly Springs, North Carolina. Spanning 65,000 m², the facility will focus on producing Genentech’s future portfolio of metabolic medicines, including next-generation obesity treatments.
The project represents an initial investment of over $700 million and is part of Roche’s $50 billion commitment to expand US manufacturing and R&D. Once complete in 2029, the facility will employ more than 1,900 people and integrate advanced automation, digital capabilities, and sustainable production practices.
Roche Group CEO Thomas Schinecker said the new facility will strengthen Roche’s US presence, expand capacity, and help deliver innovative medicines to patients worldwide. Holly Springs was chosen for its skilled workforce, strong academic ecosystem, and proximity to leading life science companies.
Set on a 400,000 m² lot with room for future expansion, the facility will enhance Roche’s global manufacturing network and ensure resilient supply chains to better serve patients.